This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Kadmon Holdings, Inc.
Drug Names(s): KD025
Description: KD025 is an orally bioavailable, potent and highly selective inhibitor of ROCK2 (Rho-associated coiled-coiled kinase 2).
ROCK2 is a central effector of a fundamental signaling pathway which serves to modify cell shape and cell migration in response to a variety of stimuli.
Additional information available to subscribers only: